These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 10716879

  • 21. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action.
    Brown SA, Lucas BA, Waid TH, McKeown JW, Barve S, Jackson LR, Thompson JS.
    Clin Transplant; 1996 Dec; 10(6 Pt 2):607-13. PubMed ID: 8996751
    [Abstract] [Full Text] [Related]

  • 22. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
    Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, Haverty T, Zivin R, Jolliffe L, Bluestone JA.
    Cancer Res; 1999 May 01; 59(9):2096-101. PubMed ID: 10232594
    [Abstract] [Full Text] [Related]

  • 23. In vivo T cell activation properties of anti-T cell monoclonal antibodies.
    Ferran C, Bach JF, Chatenoud L.
    Exp Nephrol; 1993 May 01; 1(2):83-9. PubMed ID: 8081961
    [Abstract] [Full Text] [Related]

  • 24. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
    Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S.
    Clin Transplant; 2005 Feb 01; 19(1):137-40. PubMed ID: 15659147
    [Abstract] [Full Text] [Related]

  • 25. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK, Tso JY, Waldmann TA.
    Cancer Res; 2000 Dec 15; 60(24):6977-84. PubMed ID: 11156399
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
    Böhler T, Waiser J, Lichter S, Schumann B, Neumayer HH, Kamar N, Budde K.
    Cytokine; 2008 Jun 15; 42(3):306-11. PubMed ID: 18440821
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees.
    Hsu DH, Shi JD, Homola M, Rowell TJ, Moran J, Levitt D, Druilhet B, Chinn J, Bullock C, Klingbeil C.
    Transplantation; 1999 Aug 27; 68(4):545-54. PubMed ID: 10480415
    [Abstract] [Full Text] [Related]

  • 30. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
    Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, Gagnon RC, Dal Monte P, Doyle ML, Hensley PC, Reddy MP, Sweet RW, Truneh A.
    Clin Immunol; 2001 Feb 27; 98(2):164-74. PubMed ID: 11161972
    [Abstract] [Full Text] [Related]

  • 31. Domain-switched mouse IgM/IgG2b hybrids indicate individual roles for C mu 2, C mu 3, and C mu 4 domains in the regulation of the interaction of IgM with complement C1q.
    Chen FH, Arya SK, Rinfret A, Isenman DE, Shulman MJ, Painter RH.
    J Immunol; 1997 Oct 01; 159(7):3354-63. PubMed ID: 9317134
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. CD3 antibody treatment stimulates the functional capability of regulatory T cells.
    Chatenoud L.
    Novartis Found Symp; 2003 Oct 01; 252():279-86; discussion 286-90. PubMed ID: 14609225
    [Abstract] [Full Text] [Related]

  • 35. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients.
    Roayaie S, Sheiner PA, Emre S, Guy S, Schwartz ME, Boros P, Miller CM.
    Mediators Inflamm; 2000 Oct 01; 9(3-4):141-6. PubMed ID: 11132770
    [Abstract] [Full Text] [Related]

  • 36. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation.
    Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M, O'Connell JB, Stuart F, McDiarmid SV, Wall W.
    Transpl Immunol; 1995 Sep 01; 3(3):212-21. PubMed ID: 8581409
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
    Alvarez-Rueda N, Leprieur S, Clémenceau B, Supiot S, Sébille-Rivain V, Faivre-Chauvet A, Davodeau F, Paris F, Barbet J, Aubry J, Birklé S.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
    [Abstract] [Full Text] [Related]

  • 39. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S, Yamashita K, Aoyagi T, Haga S, Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, Umezawa K, Todo S.
    Transplantation; 2006 Dec 27; 82(12):1720-7. PubMed ID: 17198266
    [Abstract] [Full Text] [Related]

  • 40. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M, Weth R, Wels WS.
    J Mol Biol; 2005 Mar 11; 346(5):1299-311. PubMed ID: 15713482
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.